Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | INCAGN02390 |
Synonyms | |
Therapy Description |
INCAGN02390 is an antibody that targets the immune inhibitory receptor TIM-3, potentially resulting in decreased tumor growth when combined with other immune checkpoint inhibitors (Cancer Res July 1 2018 (78) (13 Supplement) 3825). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
INCAGN02390 | INCAGN 02390|INCAGN-02390 | TIM-3 Antibody 9 | INCAGN02390 is an antibody that targets the immune inhibitory receptor TIM-3, potentially resulting in decreased tumor growth when combined with other immune checkpoint inhibitors (Cancer Res July 1 2018 (78) (13 Supplement) 3825). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03652077 | Phase I | INCAGN02390 | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | Completed | USA | 0 |